Listen to The Lancet Neurology

Bruce Campbell joins The Lancet Neurology to discuss his systematic review of the HERMES collaboration.

Andrew Cole (Massachusetts General Hospital Epilepsy Service, Boston, MA, USA) talks to Senior Editor Sarah Passey about the complexities underlying epilepsy in people with glioblastoma. His Review on this topic is published in the June issue of The Lancet Neurology.

Sarah Passey (The Lancet Neurology) is joined by Michael Tymianski (University Health Network, Toronto, Canada) to discuss an Article in the March issue reporting a meta-analysis looking at neuroprotection in stroke and what can be learnt for future research.

The Lancet Neurology Editors take a look back at advances in neurology in 2024, as highlighted by experts in a series of Round-ups published in the January issue.

Dr Adrian Owen joins Sarah Passey to chat about a his Personal View, published in the August 2024 issue of The Lancet Neurology, about detecting awareness after an acute brain injury.

Laura Hart and Elena Becker-Barroso speak with Niklas Mattsson-Carlgren (Lund University) about the use of blood biomarkers in the diagnosis and stratification of Alzheimer's disease.

In this episode, Senior Editor Morgane Boillot speaks with Professor Cristina Tassorelli (University of Pavia, Italy) about recent advances in migraine prevention.

Inga Zerr and Simon Mead share their insights on prion diseases with our Editor-in-Chief, Elena Becker-Barroso

Host Morgane Boillot chats with Dr Julia Greenland about a clinical trial of azathioprine in early Parkinson's disease.

In this episode, host Antonia Eisenkoeck, speaks with Ian McKeith. They delve into the history of dementia with Lewy bodies research, highlighting key milestones and breakthroughs.

In this episode, host Laura Hart chats with Ask Nordestgaard about the long-term risk of stroke in healthy women, the role of inflammation and lipoproteins, and how early biomarker screening could transform stroke prevention strategies.

Morgane Boillot chats with Professor Shiv Saidha (Johns Hopkins University, USA) about recent developments in diagnosing multiple sclerosis, and specifically on the use of paraclinical tests of the optic nerve in this context.

Morgane Boillot is joined by Professor Michael Rafii to explore the intersection of Down syndrome and Alzheimer’s disease.

In this episode, host Laura Hart chats with Professor Amit Bar-Or (University of Pennsylvania) about the potential of the BTK inhibitor fenebrutinib in treating relapsing multiple sclerosis, highlighting future challenges in MS research.

Sarah Passey is joined by Dr Marte-Helene Bjørk (Haukeland University Hospital, Norway) to discuss the latest evidence and practical guidance on managing reproductive risks in people with epilepsy, including medication safety, pregnancy planning, and global challenges in care.

Sam Griffiths is joined by Professor Geoff Manley (UCSF, CA, USA) to discuss his new NIH-NINDS classification of acute TBI, the limitations of traditional classifications, how the new framework was developed, and what it means for the future of TBI research and patient care.

Sarah Passey talks to Wayne Feng (Duke University School of Medicine, Durham, NC, USA) about his latest trial, TRANSPORT2, which assesses transcranial direct current stimulation in combination with modified constraint-induced movement therapy.

In this podcast, linked to the April 2025 issue of The Lancet Neurology, Laura Hart (Deputy Editor) chats to Marialuisa Gandolfi (University of Verona in Italy) about advances in the classification and management of pain in Parkinson’s disease.

In this podcast, linked to the February 2025 issue of The Lancet Neurology, Elena Becker-Barroso (Editor-in-Chief) chats to Elizabeth Finger (Western University, London, ON, Canada) about the FOXY trial of oxytocin for apathy in people with frontotemporal dementia.

Florian Krismer (Innsbruck Medical University) and Elizabeth Coon (Mayo Clinic) join Sarah Passey (The Lancet Neurology) to discuss their Review paper on multiple system atrophy, which is published in the December issue of The Lancet Neurology.

Professor Suvankar Pal (University of Edinburgh) joins Sarah Passey (Senior Editor at The Lancet Neurology) to discuss the first findings from the MND-SMART trial of treatments for motor neuron disease. The Article is published in the November issue of The Lancet Neurology.

Prof Jorge Correale and Dr Lilyana Amezcua talk to The Lancet Neurology about their Personal View papers, published in the October 2024 issue, on the differential diagnosis of multiple sclerosis in regions outside North America and Western Europe and in people from minority ethnic or racial backgrounds in North America, northern Europe, and Australasia.

Dr Alex Iranzo joins The Lancet Neurology to discuss his recent Review on the association between sleep disorders and Parkinson's disease. The Review is published in the August issue of The Lancet Neurology.

Dr Glenn Nielsen joins Lauren Southwell to discuss the Physio4FMD trial of specialist physiotherapy for people with functional motor disorder in England and Scotland. This Article is published in the July issue of The Lancet Neurology.

Sanjay Sisodiya joins The Lancet Neurology to discuss the potential effects of climate change on brain health. The Personal View is published in the June issue of The Lancet Neurology.

Jacqueline French and Jacob Pellinen join Senior Editor Sarah Passey to discuss recent progress made in the diagnosis of epilepsy and challenges that remain. Their Review on this topic is published in the May issue of The Lancet Neurology.

Jaimie Steinmetz and Theo Vos from the Institute of Health Metrics and Katrin Seeher and Tarun Dua from WHO join Heather Brown and Lauren Southwell to discuss new data on the global, regional, and national burden of disorders affecting the nervous system. The Article is published in the April issue of The Lancet Neurology.

Giovanni Frisoni joins The Lancet Neurology to discuss new European intersocietal recommendations for the biomarker-based diagnosis of neurocognitive disorders. The Personal View is published in the March issue of The Lancet Neurology.

Marianne Chapleau and Gil Rabinovici join Senior Editor Sarah Passey to discuss their research on posterior cortical atrophy. The Article is published in the February issue of The Lancet Neurology.

Cecilia Åkerlund and David Nelson join The Lancet Neurology to discuss their research on clinical variables that might distinguish how the disease process progresses in people with traumatic brain injury. The Article is published in the January issue of The Lancet Neurology.

Rustam Al-Shahi Salman joins Senior Editor Sarah Passey to discuss the COCROACH meta-analysis findings, published in the December issue of The Lancet Neurology, of the effects of oral anticoagulation in people with atrial fibrillation after spontaneous intracranial haemorrhage.

Njideka Okubadejo and Mie Rizig join The Lancet Neurology to discuss their comprehensive genome-wide assessment in African and African admixed individuals with the aim of developing a better understanding of the genetic architecture of Parkinson's disease in these underserved populations.

Anthony Feinstein (University of Toronto and Sunnybrook Health Sciences Centre, Toronto, Canada) discusses CogEx, a randomised trial of cognitive rehabilitation and aerobic exercise for cognitive impairment in people with progressive multiple sclerosis. The Article is published in the October issue of The Lancet Neurology.

William Jagust (University of California in Berkeley, CA, USA) talks to Senior Editor Sarah Passey about the complex pathway between amyloid β and cognition, and implications for therapy for people with Alzheimer’s disease. His Personal View on this topic is published in the September issue of The Lancet Neurology.

Stephen Strittmatter (Yale School of Medicine, CT, USA) discusses his first-in-human and randomised trial of a soluble Nogo-receptor-Fc decoy in patients with chronic cervical spinal cord injury. The Article is published in the August issue of The Lancet Neurology.

Benzi Kluger (University of Rochester Medical Center, Rochester, NY, USA), Claire Creutzfeldt (University of Washington, Seattle, WA, USA), and Malenna Sumrall (University of Colorado Anschutz Medical Campus, Aurora, CO, USA) join Jonathan Blott to discuss palliative care for individuals with neurological diseases, exploring the challenges and opportunities in enhancing the quality of life for those affected by neurological conditions. Their Review is published in the July issue of The Lancet Neurology.

Karen Duff and Connor Langworth-Green (University College London, London, UK) discuss tauopathies and the chronic effects of inflammation on this group of disorders. Their Personal View on this topic is published in the May issue of The Lancet Neurology.

Kerstin Hellwig (Ruhr University Bochum, Bochum, Germany) discusses family planning considerations in multiple sclerosis. This Review is published in the April issue of The Lancet Neurology.

Geraldine Dawson (Duke University School of Medicine, NC, USA) discusses the latest advances and ongoing challenges in prediction of autism during infancy. This Review is published in the March issue of The Lancet Neurology.

Ellisiv Mathiesen (The University of Tromsø – the Arctic University of Norway, Tromsø, Norway) discusses the findings of the TWIST trial, which investigated the use of tenecteplase for patients with wake-up stroke who were selected for treatment by non-contrast CT. This Fast-track Article is published in the February issue of The Lancet Neurology.

Beau Ances (Washington University in St Louis, MO, USA) discusses recent research on amyloid biomarkers in people with genetic forms of Alzheimer’s disease; his Article is published in the January issue of The Lancet Neurology.

Axel Petzold (National Hospital for Neurology and Neurosurgery and Moorfields Eye Hospital, London, UK, and Amsterdam University Medical Center, Amsterdam, Netherlands) discusses a Position Paper, published in the December issue of The Lancet Neurology, which sets out new criteria for the diagnosis and classification of optic neuritis.

Maeike Zijlmans (University Medical Center Utrecht, Utrecht, Netherlands) discusses recent research on tailoring of epilepsy surgery with biomarkers on intraoperative electrocorticography, and describes some of the challenges of this technique and what the future steps are for the field.

Jerome Siegel (University of California, Los Angeles, CA, USA) discusses sleep research in hunter-gatherer populations and what we can learn from the sleep habits of various species; his Review is published in the October issue of The Lancet Neurology, which is the fourth paper in The Lancet’s Series on sleep and sleep disorders.

Laurent Servais and Dora Markati (both from the University of Oxford, UK) discuss emerging therapies for Duchenne muscular dystrophy; their Review is published in the September issue of The Lancet Neurology.

Andreas Charidimou (Massachusetts General Hospital, Boston, MA, USA) discusses an international collaborative study that presents new Boston criteria for diagnosis of cerebral amyloid angiopathy; the Article is published in the August issue of The Lancet Neurology.

Sarah Tabrizi (UCL Queen Square Institute of Neurology, London, UK) and Cristina Sampaio (CHDI Foundation, Princeton, NJ, USA) discuss two papers on Huntington’s disease published in the July issue of The Lancet Neurology: a Position Paper outlining a new classification of the disease, called the Huntington’s Disease Integrated Staging System, and a Personal View on potential disease-modifying therapies.

Mark Hallett (National Institute of Neurological Disorders and Stroke, Bethesda, MD, USA) discusses his Review, published in the June issue of The Lancet Neurology, on functional neurological disorder, and talks about new subtypes of this disorder, diagnostic challenges, and how education is important.

Eva Feldman (University of Michigan, Ann Arbor, USA) discusses the latest advances in the genetics, risk factors, pathophysiology, therapeutic development, and the diagnosis and prognosis of amyotrophic lateral sclerosis; the Series is published in the May issue of The Lancet Neurology.

Estrella Morenas-Rodriguez and Christian Haass (German Centre for Neurodegenerative Diseases, Munich, Germany) discuss their recent research, published in the April issue of The Lancet Neurology, on soluble TREM2 and its association with Alzheimer’s disease biomarkers and cognition.